Systemic Lupus Erythematosus: Diagnosis, Flare Management, and Lupus Nephritis

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by loss of immune tolerance and production of autoantibodies against nuclear and cytoplasmic antigens. The disease affects multiple organ systems including skin, joints, kidneys, cardiovascular, pulmonary, and neurologic systems.

[KEY_CONCEPT] The pathophysiology involves Type II and Type III hypersensitivity reactions leading to immune complex deposition and complement activation. Key mechanisms include:

• Defective apoptosis leading to increased nuclear antigen exposure • Molecular mimicry between self and foreign antigens • Loss of B and T cell tolerance with polyclonal B cell activation • Immune complex formation and deposition in target organs • Complement consumption and inflammatory cascade activation

Epidemiology: • Prevalence: 20-150 per 100,000 population • Female predominance (9:1 ratio) • Peak onset: reproductive years (15-45 years) • Higher prevalence in African American, Hispanic, and Asian populations • Environmental triggers include infections (EBV), UV radiation, medications, and stress

[CLINICAL_PEARL] The "4 I's" contribute to SLE pathogenesis: Infections, Induction (drugs), Interference (hormones), and Inheritance (genetics).

Genetic factors include HLA-DR2, HLA-DR3, complement deficiencies (C1q, C2, C4), and mutations in genes affecting apoptosis and immune regulation.

SLE presents with diverse clinical manifestations that can mimic many other diseases, earning it the nickname "the great mimicker."

Constitutional Symptoms: • Fatigue (most common, >90% of patients) • Fever, weight loss, lymphadenopathy • Malaise and arthralgia

Musculoskeletal (95%): • Non-erosive arthritis - symmetric, involving hands, wrists, knees • Morning stiffness lasting >1 hour • Jaccoud's arthropathy - reversible deformities without erosions

Cutaneous Manifestations (80%): • Malar rash - "butterfly" distribution, spares nasolabial folds • Discoid lesions - scarring, hyperpigmented plaques • Photosensitivity - exacerbation with sun exposure • Oral/nasal ulcers - usually painless • Alopecia - patchy or diffuse

[HIGH_YIELD] SOAP BRAIN MD mnemonic for SLE features: • Serositis, Oral ulcers, Arthritis, Photosensitivity • Blood disorders, Renal disease, ANA positive, Immunologic markers • Neurologic symptoms, Malar rash, Discoid rash

Renal Disease (60%): • Lupus nephritis - most serious manifestation • Proteinuria, hematuria, hypertension • Progressive kidney dysfunction

Neuropsychiatric (60%): • Seizures, psychosis, cognitive dysfunction • Stroke, peripheral neuropathy • Depression and anxiety

Cardiopulmonary: • Pericarditis (most common cardiac manifestation) • Libman-Sachs endocarditis • Pleuritis and pleural effusions • Pulmonary hypertension

[CLINICAL_PEARL] Drug-induced lupus typically presents with constitutional symptoms, arthritis, and serositis but rarely involves kidneys or CNS. Common culprits include hydralazine, procainamide, and anti-TNF agents.

2019 EULAR/ACR Classification Criteria require:

1. Positive ANA (≥1:80 on HEp-2 cells) as entry criterion
2. Weighted scoring system with cutoff of ≥10 points

EULAR/ACR Classification Domains:

Laboratory Workup Algorithm:

Clinical Suspicion of SLE ↓ ANA Testing (HEp-2 substrate) ↓ If ANA Positive (≥1:80) ↓ ENA Panel: Anti-Sm, Anti-dsDNA, Anti-Ro/SSA, Anti-La/SSB ↓ Complement levels: C3, C4, CH50 ↓ Antiphospholipid antibodies: aCL, anti-β2GP1, LAC ↓ Complete Blood Count, Comprehensive Metabolic Panel ↓ Urinalysis with microscopy, 24-hour urine or spot protein/creatinine ↓ If renal involvement: Consider biopsy

[HIGH_YIELD] ANA Patterns and Associations: • Homogeneous - Anti-dsDNA, Anti-histone • Speckled - Anti-Sm, Anti-RNP, Anti-Ro, Anti-La • Nucleolar - Anti-Scl70, Anti-RNA polymerase • Centromere - Anti-centromere (limited cutaneous SSc)

Differential Diagnosis: • Mixed connective tissue disease - Anti-RNP positive • Sjögren's syndrome - Anti-Ro/La positive • Systemic sclerosis - Anti-Scl70 positive • Drug-induced lupus - Anti-histone positive • Rheumatoid arthritis - RF/ACCP positive, erosive arthritis

[CLINICAL_PEARL] Anti-dsDNA antibodies correlate with disease activity and lupus nephritis risk, while Anti-Sm antibodies are highly specific for SLE but don't correlate with disease activity.

SLE management requires individualized, multidisciplinary approach focusing on achieving remission and preventing organ damage.

Treatment Goals: • Achieve clinical remission or low disease activity • Prevent organ damage and flares • Minimize medication toxicity • Maintain quality of life

General Management Principles:

SLE Treatment Algorithm ↓ Lifestyle Modifications • Sun protection (SPF ≥30) • Smoking cessation • Regular exercise • Vaccination (avoid live vaccines) • Osteoporosis prevention ↓ First-line Therapy • Hydroxychloroquine 400mg daily (all patients unless contraindicated) • NSAIDs for arthritis (short-term) • Topical corticosteroids for cutaneous lesions ↓ Moderate Disease Activity • Oral prednisone 0.5-1mg/kg/day (taper rapidly) • Methotrexate 15-25mg weekly OR • Mycophenolate mofetil 1-3g daily ↓ Severe Disease/Organ-threatening • Pulse methylprednisolone 500-1000mg daily x3 days • Cyclophosphamide OR Mycophenolate mofetil • Consider rituximab or belimumab

Medication Categories:

Antimalarials: • Hydroxychloroquine - cornerstone therapy for all patients • Benefits: Reduces flares, thrombosis risk, improves survival • Monitor: Annual ophthalmologic exams

[HIGH_YIELD] Hydroxychloroquine should be continued even during remission as it reduces flare risk by 50% and has protective cardiovascular effects.

Corticosteroids: • Prednisone - short-term use, lowest effective dose • Pulse methylprednisolone - severe flares • Goal: Taper to <7.5mg/day prednisone

Immunosuppressants: • Methotrexate 15-25mg weekly - arthritis, skin manifestations • Mycophenolate mofetil 1-3g daily - nephritis, general immunosuppression • Azathioprine 1-3mg/kg daily - maintenance therapy • Cyclophosphamide - severe nephritis, neuropsychiatric lupus

Biologics: • Belimumab (anti-BAFF) - active SLE despite standard therapy • Rituximab (anti-CD20) - severe refractory disease • Anifrolumab (anti-interferon) - moderate to severe SLE

Flare Management:

[CLINICAL_PEARL] Treat-to-target approach aims for SLEDAI-2K ≤2 or clinical remission defined as no clinical activity with prednisone ≤5mg daily and maintenance immunosuppression.

Lupus nephritis occurs in 60% of SLE patients and is the leading cause of morbidity and mortality. Early recognition and aggressive treatment are crucial for preserving renal function [1].

Classification (ISN/RPS 2003): • Class I - Minimal mesangial (rare) • Class II - Mesangial proliferative (mild) • Class III - Focal proliferative (<50% glomeruli) • Class IV - Diffuse proliferative (>50% glomeruli) • Class V - Membranous nephropathy • Class VI - Advanced sclerosing (>90% sclerosed)

[HIGH_YIELD] Classes III and IV are considered proliferative nephritis requiring aggressive immunosuppression, while Class V may be managed less aggressively unless combined with proliferative features.

Screening and Monitoring [1]: • Urinalysis with microscopy every 3 months • Spot urine protein/creatinine ratio • Serum creatinine and estimated GFR • Complement levels (C3, C4) • Anti-dsDNA antibodies

Indications for Renal Biopsy: • Proteinuria >0.5g/day • Active urinary sediment (RBC casts, dysmorphic RBCs) • Rising serum creatinine without other explanation • Combination of proteinuria + hematuria + low complement

Treatment Algorithm:

Proliferative LN (Class III/IV) ↓ Induction Therapy (6 months) • Mycophenolate mofetil 2-3g daily OR • Cyclophosphamide (Euro-Lupus: 500mg IV q2weeks x6) • PLUS Prednisone 1mg/kg daily (max 60mg) x4-6 weeks, then taper ↓ Response Assessment at 6 months ↓ Complete Response (proteinuria <0.5g/day, normal/stable GFR) ↓ Maintenance Therapy • Mycophenolate mofetil 1-2g daily OR • Azathioprine 2mg/kg daily • Prednisone ≤5-10mg daily ↓ Partial Response (≥50% reduction proteinuria) ↓ Continue induction therapy OR switch agents ↓ No Response ↓ Switch to alternative induction regimen Consider rituximab, calcineurin inhibitors

2024 ACR Guidelines Key Recommendations [1]: • Strong recommendation for mycophenolate mofetil over cyclophosphamide for induction in most patients • Conditional recommendation for initial combination therapy with calcineurin inhibitors in severe cases • Strong recommendation for maintenance therapy duration of at least 3 years • Conditional recommendation for rituximab in refractory cases

Membranous Lupus Nephritis (Class V): • Mycophenolate mofetil or calcineurin inhibitors for proteinuria >2g/day • ACE inhibitors/ARBs for proteinuria and blood pressure control • Rituximab for refractory cases

Treatment Response Definitions: • Complete response - Proteinuria <0.5g/day, normal/stable GFR, inactive sediment • Partial response - ≥50% reduction in proteinuria, stable GFR • No response - <50% reduction in proteinuria or rising creatinine

[CLINICAL_PEARL] Lupus nephritis flares often occur silently, making regular monitoring essential. Rising anti-dsDNA and falling complement levels may precede clinical nephritis by months.

Disease Activity Monitoring requires regular assessment using validated tools and laboratory markers to guide treatment decisions and prevent organ damage.

Disease Activity Indices: • SLEDAI-2K - 24-item scale, scores 0-105 • BILAG-2004 - categorical scoring (A-E grades) • PGA - Physician global assessment (0-3 scale)

Routine Monitoring Schedule:

Organ Damage Assessment: • SLICC/ACR Damage Index - irreversible organ damage • Common sites: CNS, renal, cardiovascular, musculoskeletal • Prevention focus - early aggressive treatment

Cardiovascular Risk Management: [HIGH_YIELD] SLE patients have 2-3 fold increased cardiovascular risk due to: • Chronic inflammation • Accelerated atherosclerosis • Traditional risk factors (hypertension, diabetes) • Medication effects (corticosteroids)

Prevention strategies: • Statin therapy for patients >40 years or with additional risk factors • Antihypertensive therapy - target <130/80 mmHg • Diabetes management - HbA1c <7% • Smoking cessation • Hydroxychloroquine - cardioprotective effects

Pregnancy Considerations: • Pre-pregnancy counseling essential • Disease should be quiescent for 6 months before conception • Safe medications - HCQ, prednisone, azathioprine • Contraindicated - MTX, MMF, cyclophosphamide • Monitor for - preeclampsia, flares, neonatal lupus

Long-term Prognosis: • 10-year survival - 90-95% in developed countries • 20-year survival - 80-90% • Poor prognostic factors:

• Lupus nephritis (especially Class IV)
• CNS involvement
• Antiphospholipid syndrome
• Male gender
• Early age of onset
• High disease activity

Quality of Life Factors: • Fatigue - most common persistent symptom • Pain management - multimodal approach • Mood disorders - screen and treat depression/anxiety • Social support - patient education and support groups

[CLINICAL_PEARL] Remission is achievable in most SLE patients with early, aggressive treatment. The goal is clinical remission (SLEDAI-2K ≤2) on minimal corticosteroids (≤5mg prednisone daily) with maintenance immunosuppression.

Vaccination Recommendations: • Annual influenza vaccine (inactivated) • Pneumococcal vaccines (PCV13 and PPSV23) • COVID-19 vaccination (mRNA preferred) • Avoid live vaccines while on immunosuppression • Vaccination timing - ideally when disease is stable and before starting biologics